JPMorgan Chase & Co. raised its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 619.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 252,870 shares of the biopharmaceutical company’s stock after buying an additional 217,724 shares during the period. JPMorgan Chase & Co. owned 0.45% of TG Therapeutics worth $2,946,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Thompson Davis & CO. Inc. acquired a new position in shares of TG Therapeutics during the first quarter valued at about $154,000. North Star Investment Management Corp. raised its position in shares of TG Therapeutics by 110.0% in the first quarter. North Star Investment Management Corp. now owns 21,000 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 11,000 shares during the last quarter. Raymond James Financial Services Advisors Inc. acquired a new position in shares of TG Therapeutics during the fourth quarter valued at about $143,000. Creative Planning raised its position in shares of TG Therapeutics by 3.2% in the first quarter. Creative Planning now owns 32,001 shares of the biopharmaceutical company’s stock valued at $373,000 after buying an additional 1,000 shares during the last quarter. Finally, Bank of Montreal Can acquired a new position in shares of TG Therapeutics during the first quarter valued at about $443,000. 45.68% of the stock is owned by hedge funds and other institutional investors.

Shares of TG Therapeutics, Inc. (NASDAQ TGTX) traded down 1.48% during mid-day trading on Tuesday, reaching $10.00. 1,156,238 shares of the company traded hands. TG Therapeutics, Inc. has a 52 week low of $4.10 and a 52 week high of $15.35. The stock’s 50-day moving average is $11.07 and its 200-day moving average is $9.79. The company’s market capitalization is $616.56 million.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.10. TG Therapeutics had a negative return on equity of 135.31% and a negative net margin of 60,613.16%. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. On average, equities analysts predict that TG Therapeutics, Inc. will post ($1.81) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/08/jpmorgan-chase-co-buys-217724-shares-of-tg-therapeutics-inc-nasdaqtgtx-updated-updated-updated.html.

TGTX has been the topic of several analyst reports. BidaskClub lowered shares of TG Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, July 6th. Zacks Investment Research raised shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Thursday, July 13th. Raymond James Financial, Inc. reiterated a “buy” rating on shares of TG Therapeutics in a research note on Friday, April 21st. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a research note on Monday, May 1st. Finally, Jefferies Group LLC started coverage on shares of TG Therapeutics in a research report on Tuesday, April 25th. They set a “buy” rating and a $23.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $23.67.

In other TG Therapeutics news, CFO Sean A. Power sold 59,976 shares of the stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $11.09, for a total transaction of $665,133.84. Following the transaction, the chief financial officer now owns 477,464 shares in the company, valued at $5,295,075.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 16.70% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.